Sobi names former Shire exec to head North American business

Swedish Orphan Biovitrum (STO: SOBI), the Nordic biotech company known as Sobi, has appointed Amy Pott as the new head of Sobi North America. She takes over effective today, replacing Rami Levin who is leaving Sobi.

“Sobi North America is entering a new phase in line with Sobi’s growth strategy, with the workforce growing more than fourfold in just more than a year. The launch of Gamifant [emapalumab] and the integration of Synagis are key to the company’s future and I am delighted to welcome Amy to Sobi for her to take on this challenge,” says Guido Oelkers, chief executive.

Ms Pott was most recently group vice president and US franchise head for Internal Medicine & Oncology at Shire, which has recently been acquired by Japan’s Takeda (TYO: 4502). She was also group VP for US Commercial Operations at Shire and VP of strategy, planning and analytics at Baxalta, all roles based in Boston. Prior to her roles in the USA, Ms Pott spent 10 years at Baxter, where she held UK and international roles working with both rare diseases and medical devices. During her time in the UK she built up Baxter’s UK & Ireland market access team.